Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 on April 1, 2026 to include the consent of Deloitte & Touche LLP to its report dated March 31, 2026 relating to financial statements in the Annual Report on Form 10-K for the year ended December 31, 2025. The amendment is an exhibit-only filing under Rule 462(d) and does not change the prospectus or the balance of Part II of the Registration Statement.
Tvardi Therapeutics (TVRD) files a prospectus supplement registering the resale of up to 2,084,117 shares of common stock by selling stockholders pursuant to the Merger Agreement. The supplement attaches portions of the Form 10-K for the fiscal year ended December 31, 2025, and updates disclosure with clinical and corporate information.
The 10-K describes Tvardi’s pipeline focused on direct STAT3 inhibitors (TTI-101 and prodrug TTI-109), clinical programs in IPF and HCC, Phase 1 and Phase 2 trial details, IND acceptance for TTI-109, certain preclinical findings, patent and license arrangements with Baylor College of Medicine, and corporate reorganizations following the Merger. Shares outstanding were 9,381,344 as of March 26, 2026.
Tvardi Therapeutics, Inc. files its Form 10-K describing a clinical-stage pipeline of oral STAT3 inhibitors aimed at inflammatory and proliferative diseases. The company’s lead drug, TTI-101, is in a Phase 1b/2 REVERT LIVER CANCER trial for hepatocellular carcinoma, while TTI-109, a phosphate prodrug of TTI-101, is in a Phase 1 study in healthy volunteers with topline data expected in the second quarter of 2026.
The report explains how a 2025 merger with Cara Therapeutics created the current Tvardi entity, summarizes mixed IPF Phase 2 results that nonetheless showed biomarker and fibrosis improvements consistent with preclinical models, and details extensive global patent coverage and Baylor College of Medicine license agreements supporting long-lived intellectual property around TTI-101 and TTI-109.
Tvardi Therapeutics reported fourth quarter and full-year 2025 results showing lower expenses and a narrower loss while advancing its STAT3 inhibitor pipeline. Research and development spending fell to $5.5 million in the quarter and $18.0 million for 2025, down from $8.6 million and $23.7 million in 2024, mainly as TTI-101 clinical costs declined.
Net loss improved to $7.3 million for the quarter and $18.2 million for the year, compared with $12.7 million and $29.4 million a year earlier. Cash, cash equivalents and short-term investments totaled $30.8 million as of December 31, 2025, and the company expects this to fund operations through key clinical readouts and into the fourth quarter of 2026.
The company highlighted upcoming milestones, including healthy volunteer data for next-generation STAT3 inhibitor TTI-109 in Q2 2026 and topline Phase 2 data for TTI-101 in hepatocellular carcinoma in the second half of 2026.
Tvardi Therapeutics files a prospectus supplement for the resale of up to 2,084,117 shares of common stock. The supplement updates the prospectus dated November 8, 2025 with information from Current Reports on Form 8-K filed December 18, 2025 and March 6, 2026. The resale shares were issued to certain selling stockholders pursuant to the Merger Agreement dated December 17, 2024.
The supplement states the Nasdaq last reported sale price was $4.02 on March 5, 2026. The supplement also attaches excerpts of two 8-Ks disclosing retention option grants, a severance and change-in-control plan, and the company’s 2026 annual meeting date and proxy submission deadlines.
Tvardi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026. Stockholder proposals seeking inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at the principal executive offices by March 16, 2026.
For other business or director nominations brought directly before the meeting under the company’s Amended and Restated Bylaws, stockholders must also submit notice by March 16, 2026. Separate notice for soliciting proxies in support of alternative director nominees in compliance with SEC Rule 14a-19 is due by April 10, 2026.
Tvardi Therapeutics, Inc. received an amended Schedule 13G filing from investor Ronald A. DePinho, reporting his beneficial ownership of the company’s common stock. As of December 31, 2025, he beneficially owned 426,190 shares, including 3,635 shares held through an entity he controls.
This stake represents 4.5% of Tvardi’s common stock, based on 9,381,344 shares outstanding as of November 10, 2025, as reported in Tvardi’s Form 10-Q. DePinho has sole voting and dispositive power over all reported shares and indicates that the holdings are not for the purpose of changing or influencing control of the company.
Tvardi Therapeutics, Inc. reported that Principal Accounting Officer Stephen Paul O'Brien received an employee stock option award on January 29, 2026. The option gives him the right to buy 15,000 shares of common stock at an exercise price of $3.90 per share.
The option vests in equal monthly installments over 48 months starting January 29, 2026, so vesting continues as long as he remains in continuous service with the company. The option expires on January 29, 2036, and all 15,000 derivative securities are reported as directly owned after this grant.
Tvardi Therapeutics, Inc. reported that its Chief Financial Officer, Avi Daniel Conn, received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share, expiring January 29, 2036.
The options vest in equal monthly installments over 48 months, starting January 29, 2026, as long as Conn remains in continuous service through each vesting date. Following this grant, Conn holds 45,000 derivative securities directly.
Tvardi Therapeutics, Inc. reported that its Chief Medical Officer, Kauh John Saewook, M.D., received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share.
These options vest in equal monthly installments over 48 months starting January 29, 2026, as long as the executive remains in continuous service. Following this grant, the reporting person beneficially owns 45,000 derivative securities, all held as direct ownership.